Evidence map›Paper›PMID 31451441›Full record

ArticleThe Lancet. Global health2019

The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study.

Sophie Uyoga, Alex W Macharia, George Mochamah, Carolyne M Ndila, Gideon Nyutu, Johnstone Makale, Metrine Tendwa, Emily Nyatichi, John Ojal, Mark Otiende and 8 more

Abstract read
In one paragraph

Article in The Lancet. Global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Sophie UyogaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Alex W MachariaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
George MochamahKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Carolyne M NdilaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Gideon NyutuKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Johnstone MakaleKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Metrine TendwaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Emily NyatichiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
John OjalKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Mark OtiendeKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Mohammed ShebeKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Kennedy O AwuondoKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Neema MturiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Norbert PeshuKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Benjamin TsofaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Kathryn MaitlandKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Faculty of Medicine, Imperial College, St Mary's Hospital, London, UK.
J Anthony G ScottKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; London School of Hygiene & Tropical Medicine, London, UK; INDEPTH Network, Accra, Ghana.
Thomas N WilliamsKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; London School of Hygiene & Tropical Medicine, London, UK; INDEPTH Network, Accra, Ghana. Electronic address: twilliams@kemri-wellcome.org.

Funding

Wellcome Trust 202800/Z/16/Z
6 · The paper itself

Abstract

backgroundSickle cell disease is the most common severe monogenic disorder in humans. In Africa, 50-90% of children born with sickle cell disease die before they reach their fifth birthday. In this study, we aimed to describe the comparative incidence of specific clinical outcomes among children aged between birth and 5 years with and without sickle cell disease, who were resident within the Kilifi area of Kenya.

methodsThis prospective cohort study was done on members of the Kilifi Genetic Birth Cohort Study (KGBCS) on the Indian Ocean coast of Kenya. Recruitment to the study was facilitated through the Kilifi Health and Demographic Surveillance System (KHDSS), which covers a resident population of 260 000 people, and was undertaken between Jan 1, 2006, and April 30, 2011. All children who were born within the KHDSS area and who were aged 3-12 months during the recruitment period were eligible for inclusion. Participants were tested for sickle cell disease and followed up for survival status and disease-specific admission to Kilifi County Hospital by passive surveillance until their fifth birthday. Children with sickle cell disease were offered confirmatory testing and care at a dedicated outpatient clinic.

findings15 737 infants were recruited successfully to the KGBCS, and 128 (0·8%) of these infants had sickle cell disease, of whom 70 (54·7%) enrolled at the outpatient clinic within 12 months of recruitment. Mortality was higher in children with sickle cell disease (58 per 1000 person-years of observation, 95% CI 40-86) than in those without sickle cell disease (2·4 per 1000 person-years of observation, 2·0-2·8; adjusted incidence rate ratio [IRR] 23·1, 95% CI 15·1-35·3). Among children with sickle cell disease, mortality was lower in those who enrolled at the clinic (adjusted IRR 0·26, 95% CI 0·11-0·62) and in those with higher levels of haemoglobin F (HbF; adjusted IRR 0·40, 0·17-0·94). The incidence of admission to hospital was also higher in children with sickle cell disease than in children without sickle cell disease (210 per 1000 person-years of observation, 95% CI 174-253, vs 43 per 1000 person-years of observation, 42-45; adjusted IRR 4·80, 95% CI 3·84-6·15). The most common reason for admission to hospital among those with sickle cell disease was severe anaemia (incidence 48 per 1000 person-years of observation, 95% CI 32-71). Admission to hospital was lower in those with a recruitment HbF level above the median (IRR 0·43, 95% CI 0·24-0·78; p=0·005) and those who were homozygous for α-thalassaemia (0·07, 0·01-0·83; p=0·035).

interpretationAlthough morbidity and mortality were high in young children with sickle cell disease in this Kenyan cohort, both were reduced by early diagnosis and supportive care. The emphasis must now move towards early detection and prevention of long-term complications of sickle cell disease.

fundingWellcome Trust.

Indexed as

Anemia, Sickle CellChild, PreschoolHumansIncidenceInfantInfant, NewbornKenyaProspective Studies

Identifiers

PMID31451441
PMCPMC7024980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.